Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07115004) titled 'Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)' on Aug. 4.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Vega Therapeutics, Inc

Condition: Von Willebrand Disease (VWD)

Intervention: Drug: VGA039

Recruitment Status: Recruiting

Phase: Phase 3

Date of First Enrollment: September 1, 2025

Target Sample Size: 60

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07115004

Published by HT Digit...